{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T03:45:55Z","timestamp":1789962355607,"version":"4.0.1"},"reference-count":59,"publisher":"Akademiai Kiado Zrt.","issue":"21","license":[{"start":{"date-parts":[[2022,5,22]],"date-time":"2022-05-22T00:00:00Z","timestamp":1653177600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["akjournals.com"],"crossmark-restriction":true},"short-container-title":["OH"],"published-print":{"date-parts":[[2022,5,22]]},"abstract":"<jats:p>A nem alkoholos zs\u00edrm\u00e1jbetegs\u00e9g (NAFLD) ma a leggyakoribb m\u00e1jbetegs\u00e9g, a vil\u00e1g\n                    n\u00e9pess\u00e9g\u00e9nek 25%-\u00e1t \u00e9rinti. A k\u00f3rk\u00e9p \u00e9s progressz\u00edv form\u00e1ja, a nem alkoholos\n                    steatohepatitis gyakran t\u00e1rsul obesitassal \u00e9s 2-es t\u00edpus\u00fa cukorbetegs\u00e9ggel.\n                    NAFLD-ben 2\u20133-szoros a diabetes kock\u00e1zata, ami p\u00e1rhuzamosan n\u0151 a m\u00e1jbetegs\u00e9g\n                    s\u00falyoss\u00e1g\u00e1val. Mivel komplex kapcsolat van a k\u00e9t k\u00f3rk\u00e9p k\u00f6z\u00f6tt, a zs\u00edrm\u00e1j \u00e9s a\n                    diabetes szinergikusan hat a kedvez\u0151tlen klinikai kimenetelre. Cukorbetegekben\n                    gyakori a zs\u00edrm\u00e1j, \u00e9s a diabetes NAFLD-ben prediktora a steatohepatitisbe,\n                    fibrosisba, cirrhosisba val\u00f3 progresszi\u00f3nak. A genetikai faktorok mellett a\n                    t\u00falzott kal\u00f3riabevitel, a zs\u00edrsz\u00f6vet diszfunkci\u00f3ja, az inzulinrezisztencia, a\n                    szabad zs\u00edrsavak \u00e9s gyullad\u00e1sos citokinek, valamint a lipo- \u00e9s gl\u00fckotoxicit\u00e1s\n                    szerepe meghat\u00e1roz\u00f3 a NAFLD \u00e9s a diabetes kialakul\u00e1s\u00e1ban. A dolgozatban\n                    \u00e1ttekintj\u00fck a k\u00e9t k\u00f3rk\u00e9pet \u00f6sszek\u00f6t\u0151 patomechanizmusokat. Orv Hetil. 2022;\n                    13(21): 815\u2013825.<\/jats:p>","DOI":"10.1556\/650.2022.32479","type":"journal-article","created":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T08:36:23Z","timestamp":1668760583000},"page":"815-825","update-policy":"https:\/\/doi.org\/10.1556\/policypage.crossmark.crossref.1","source":"Crossref","is-referenced-by-count":8,"title":["A nem alkoholos zs\u00edrm\u00e1jbetegs\u00e9g \u00e9s a 2-es t\u00edpus\u00fa cukorbetegs\u00e9g."],"prefix":"10.1556","volume":"163","author":[{"given":"Alajos","family":"P\u00e1r","sequence":"first","affiliation":[{"name":"P\u00e9csi Tudom\u00e1nyegyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Klinikai K\u00f6zpont, I. Belgy\u00f3gy\u00e1szati Klinika P\u00e9cs, Ifj\u00fas\u00e1g u. 13., 7624 Magyarorsz\u00e1g"},{"name":"P\u00e9csi Tudom\u00e1nyegyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Klinikai K\u00f6zpont, II. Belgy\u00f3gy\u00e1szati Klinika \u00e9s Nephrol\u00f3giai, Diabetol\u00f3giai Centrum P\u00e9cs Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Istv\u00e1n","family":"Wittmann","sequence":"additional","affiliation":[{"name":"P\u00e9csi Tudom\u00e1nyegyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Klinikai K\u00f6zpont, II. Belgy\u00f3gy\u00e1szati Klinika \u00e9s Nephrol\u00f3giai, Diabetol\u00f3giai Centrum P\u00e9cs Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"P\u00e1r","sequence":"additional","affiliation":[{"name":"P\u00e9csi Tudom\u00e1nyegyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Klinikai K\u00f6zpont, I. Belgy\u00f3gy\u00e1szati Klinika P\u00e9cs, Ifj\u00fas\u00e1g u. 13., 7624 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"425","reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.jhep.2018.10.033","article-title":"Non-alcoholic fatty liver disease - a global public health perspective","volume":"70","author":"1 Younossi","year":"2019","unstructured":"1 Younossi ZM. Non-alcoholic fatty liver disease - a global public health perspective. J Hepatol. 2019; 70: 531-544.","journal-title":"J Hepatol"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"71","author":"2 Younossi","year":"2019","unstructured":"2 Younossi ZM, Golabi P, de Avia L, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol. 2019; 71: 793-801.","journal-title":"J Hepatol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/S0002-9343(99)00271-5","article-title":"Association of nonalcoholic fatty liver disease with insulin resistance","volume":"107","author":"3 Marchesini","year":"1999","unstructured":"3 Marchesini G, Brizi M, Morselli-Labate AM, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med. 1999; 107: 450-455.","journal-title":"Am J Med"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/S2213-8587(14)70032-4","article-title":"Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome","volume":"2","author":"4 Yki-J\u00e4rvinen","year":"2014","unstructured":"4 Yki-J\u00e4rvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol. 2014; 2: 901-910.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref4","unstructured":"5 Pepper W. Saccharine diabetes. Med Rec. 1884; 25: 9-12."},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6 Thaler H. Fatty liver, its causes and concomitant diseases. [Die Fettleber, ihre Ursachen und Begleitkrankheiten.] Dtsch Med Wochenschr. 1962; 87: 1049-1055. [German]","DOI":"10.1055\/s-0028-1111865"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1002\/hep.27981","article-title":"Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: the Rotterdam study","volume":"63","author":"7 Koehler","year":"2016","unstructured":"7 Koehler EM, Plompen EP, Schouten JN, et al. Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: the Rotterdam study. Hepatology 2016; 63: 138-147.","journal-title":"Hepatology"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1111\/liv.13994","article-title":"Causality between non-alcoholic fatty liver disease and risk of cardiovascular disease and type 2 diabetes: a meta-analysis with bias analysis","volume":"39","author":"8 Morrison","year":"2019","unstructured":"8 Morrison AE, Zaccardi F, Khunti K, et al. Causality between non-alcoholic fatty liver disease and risk of cardiovascular disease and type 2 diabetes: a meta-analysis with bias analysis. Liver Int. 2019; 39: 557-567.","journal-title":"Liver Int"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.jhepr.2019.07.002","article-title":"From NASH to diabetes and from diabetes to NASH: mechanisms and treatment options","volume":"1","author":"Gastaldelli A","year":"2019","unstructured":"9 Gastaldelli A, Cusi K. From NASH to diabetes and from diabetes to NASH: mechanisms and treatment options. JHEP Rep. 2019; 1: 312-328.","journal-title":"JHEP Rep"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1002\/hep4.1479","article-title":"Pathogenesis of nonalcoholic steatohepatitis: an overview","volume":"4","author":"10 Parthasarathy","year":"2020","unstructured":"10 Parthasarathy G, Revelo X, Malhi H. Pathogenesis of nonalcoholic steatohepatitis: an overview. Hepatol Commun. 2020; 4: 478-492.","journal-title":"Hepatol Commun"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11 Targher G, Corey KE, Byrne CD, et al. The complex link between NAFLD and type 2 diabetes mellitus. Mechanisms and treatments. Nat Rev Gastroenterol Hepatol. 2021; 18: 599-612.","DOI":"10.1038\/s41575-021-00448-y"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1136\/gutjnl-2020-322572","article-title":"Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals","volume":"70","author":"12 Mantovani","year":"2021","unstructured":"12 Mantovani AP, Petracca G, Beatrice G, et al. Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals. Gut 2021; 70: 962-969.","journal-title":"Gut"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction- associated fatty liver disease: an international expert consensus statement","volume":"73","author":"13 Eslam","year":"2020","unstructured":"13 Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction- associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020; 73: 202-209.","journal-title":"J Hepatol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1002\/hep.31420","article-title":"From NAFLD to MAFLD: implications of a premature change in terminology","volume":"73","author":"14 Younossi","year":"2021","unstructured":"14 Younossi ZM, Rinella ME, Sanyal AJ, et al. From NAFLD to MAFLD: implications of a premature change in terminology. Hepatology 2021; 73: 1194-1198.","journal-title":"Hepatology"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15 P\u00e1r A, P\u00e1r G. Advances in the pathogenesis of non alcoholic fatty liver disease. [\u00dajabb adatok a nem alkoholos zs\u00edrm\u00e1j patogenezis\u00e9hez.] Orv Hetil. 2017; 58: 882-894. [Hungarian]","DOI":"10.1556\/650.2017.30775"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/nrgastro.2016.147","article-title":"NAFLD and diabetes mellitus","volume":"14","author":"16 Tilg","year":"2017","unstructured":"16 Tilg H, Moschen AR, Roden M. NAFLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol. 2017; 14: 32-42.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"17 Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015; 62(Suppl 1): S47-S64.","DOI":"10.1016\/j.jhep.2014.12.012"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1002\/hep.31095","article-title":"Ceramides: a cause of insulin resistance in nonalcoholic fatty liver disease in both murine models and humans","volume":"71","author":"18 Yki-J\u00e4rvinen","year":"2020","unstructured":"18 Yki-J\u00e4rvinen H. Ceramides: a cause of insulin resistance in nonalcoholic fatty liver disease in both murine models and humans. Hepatology 2020; 71: 1499-1501.","journal-title":"Hepatology"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1146\/annurev-physiol-021115-105331","article-title":"Pathophysiology and mechanisms of nonalcoholic fatty liver disease","volume":"78","author":"19 Haas","year":"2016","unstructured":"19 Haas JT, Francque S, Staels B. Pathophysiology and mechanisms of nonalcoholic fatty liver disease. Annu Rev Physiol. 2016; 78: 181-205.","journal-title":"Annu Rev Physiol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1038\/ng.257","article-title":"Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease","volume":"40","author":"20 Romeo","year":"2008","unstructured":"20 Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008; 40: 1461-1465.","journal-title":"Nat Genet"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"9521","DOI":"10.1073\/pnas.1901974116","article-title":"Accumulation of PNPLA3 on lipid droplets is the basis of associated hepatic steatosis","volume":"116","author":"21 BasuRay","year":"2019","unstructured":"21 BasuRay S, Wang Y, Smagris E. Accumulation of PNPLA3 on lipid droplets is the basis of associated hepatic steatosis. Proc Natl Acad Sci USA 2019; 116: 9521-9526.","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1002\/hep.30350","article-title":"17-Beta hydroxysteroid dehydrogenase 13 is a hepatic retinol dehydrogenase associated with histological features of nonalcoholic fatty liver disease","volume":"69","author":"22 Ma","year":"2019","unstructured":"22 Ma Y, Belyaeva OV, Brown PM, et al. Nonalcoholic Steatohepatitis Clinical Research Network. 17-Beta hydroxysteroid dehydrogenase 13 is a hepatic retinol dehydrogenase associated with histological features of nonalcoholic fatty liver disease. Hepatology 2019; 69: 1504-1519.","journal-title":"Hepatology"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"23 Gastaldelli A. Insulin resistance and reduced metabolic flexibility: cause or consequence of NAFLD? Clin Sci. 2017; 131: 2701-2704.","DOI":"10.1042\/CS20170987"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"24 Taylor R, Al-Mrabeh A, Zhyzhneuskaya S, et al. Remission of human type 2 diabetes requires decrease in liver and pancreas fat content but is dependent upon capacity for beta cell recovery. Cell Metab. 2018; 28: 547-556.e3. [Erratum: Cell Metab. 2018; 28: 667.]","DOI":"10.1016\/j.cmet.2018.07.003"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"25 Ampuero J, Aller R, Gallego-Dur\u00e1n R, et al. Significant fibrosis predicts new onset diabetes mellitus and arterial hypertension in patients with NASH. J Hepatol. J Hepatol. 2020; 73: 740-741. Erratum: J Hepatol. 2020; 73: 17-25.","DOI":"10.1016\/j.jhep.2020.06.018"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"26 Musso G, Cassader M, Paschetta E, et al. Bioactive lipid species and metabolic pathways in progression and resolution of nonalcoholic steatohepatitis. Gastroenterology 2018; 155: 282-302.e8.","DOI":"10.1053\/j.gastro.2018.06.031"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1136\/gutjnl-2017-315691","article-title":"Non-alcoholic steatohepatitis pathogenesis: sublethal hepatocyte injury as a driver of liver inflammation","volume":"67","author":"27 Ibrahim","year":"2018","unstructured":"27 Ibrahim SH, Hirsova P, Gores GJ. Non-alcoholic steatohepatitis pathogenesis: sublethal hepatocyte injury as a driver of liver inflammation. Gut 2018; 67: 963-972.","journal-title":"Gut"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"3313","DOI":"10.1007\/s00018-018-2860-6","article-title":"Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease","volume":"75","author":"28 Ipsen","year":"2018","unstructured":"28 Ipsen DH, Lykkesfeldt J, Tveden-Nyborg P. Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease. Cell Mol Life Sci. 2018; 75: 3313-3327.","journal-title":"Cell Mol Life Sci"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1111\/j.1464-5491.2009.02847.x","article-title":"Role of glucotoxicity and lipotoxicity in the pathophysiology of type 2 diabetes mellitus and emerging treatment strategies","volume":"26","author":"29 Del Prato","year":"2009","unstructured":"29 Del Prato S. Role of glucotoxicity and lipotoxicity in the pathophysiology of type 2 diabetes mellitus and emerging treatment strategies. Diabet Med. 2009; 26: 1185-1192.","journal-title":"Diabet Med"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.metabol.2010.03.006","article-title":"Plasma metabolomic profile in nonalcoholic fatty liver disease","volume":"60","author":"30 Kalhan","year":"2011","unstructured":"30 Kalhan SC, Guo L, Edmison J, et al. Plasma metabolomic profile in nonalcoholic fatty liver disease. Metabolism 2011; 60: 404-413.","journal-title":"Metabolism"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/nrendo.2014.60","article-title":"Beyond intestinal soap - bile acids in metabolic control","volume":"10","author":"31 Kuipers","year":"2014","unstructured":"31 Kuipers F, Bloks VW, Groen AK. Beyond intestinal soap - bile acids in metabolic control. Nat Rev Endocrinol. 2014; 10: 488-498.","journal-title":"Nat Rev Endocrinol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"140","DOI":"10.5625\/lar.2018.34.4.140","article-title":"Crosstalk between FXR and TGR5 controls glucagon-like peptide 1 secretion to maintain glycemic homeostasis","volume":"34","author":"Kim H","year":"2018","unstructured":"32 Kim H, Fang S. Crosstalk between FXR and TGR5 controls glucagon-like peptide 1 secretion to maintain glycemic homeostasis. Lab Anim Res. 2018; 34: 140-146.","journal-title":"Lab Anim Res"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"11055","DOI":"10.1074\/jbc.M117.784322","article-title":"Farnesoid X receptor induces Takeda G-protein receptor 5 cross-talk to regulate bile acid synthesis and hepatic metabolism","volume":"292","author":"33 Pathak","year":"2017","unstructured":"33 Pathak P, Liu H, Boehme S, et al. Farnesoid X receptor induces Takeda G-protein receptor 5 cross-talk to regulate bile acid synthesis and hepatic metabolism. J Biol Chem. 2017; 292: 11055-11069.","journal-title":"J Biol Chem"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1002\/eji.201847485","article-title":"Innate immune cells orchestrate the repair of sterile injury in the liver and beyond","volume":"49","author":"Hossain M","year":"2019","unstructured":"34 Hossain M, Kubes P. Innate immune cells orchestrate the repair of sterile injury in the liver and beyond. Eur J Immunol. 2019; 49: 831-841.","journal-title":"Eur J Immunol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41575-019-0210-2","article-title":"Adaptive immunity: an emerging player in the progression of NAFLD","volume":"17","author":"Sutti S","year":"2020","unstructured":"35 Sutti S, Albano E. Adaptive immunity: an emerging player in the progression of NAFLD. Nat Rev Gastroenterol Hepatol. 2020; 17: 81-92.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref35","unstructured":"36 Zhang S, Ma C, Wang X, et al. Impact of chronic psychological stress on nonalcoholic fatty liver disease. Int J Clin Exp Med. 2019; 12: 7991-7998."},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.3390\/biomedicines9111697","article-title":"Non-alcoholic fatty liver disease (NAFLD) and potential links to depression, anxiety and chronic stress","volume":"9","author":"37 Shea","year":"2021","unstructured":"37 Shea S, Lionis C, Kite C, et al. Non-alcoholic fatty liver disease (NAFLD) and potential links to depression, anxiety and chronic stress. Biomedicines 2021; 9: 1697.","journal-title":"Biomedicines"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"611","DOI":"10.3389\/fendo.2019.00611","article-title":"Gut dysfunction and non-alcoholic fatty liver disease","volume":"10","author":"38 Grabherr","year":"2019","unstructured":"38 Grabherr F, Grander C, Effenberger M, et al. Gut dysfunction and non-alcoholic fatty liver disease. Front Endocrinol. 2019; 10: 611.","journal-title":"Front Endocrinol"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"39 Malhi H. Emerging role of extracellular vesicles in liver diseases. Am J Physiol Gastrointest Liver Physiol. 2019; 317: G739-G749.","DOI":"10.1152\/ajpgi.00183.2019"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41575-019-0212-0","article-title":"Genetic contibutions to NAFLD: leveraging shared genetics to uncover systems biology","volume":"17","author":"Eslam M","year":"2020","unstructured":"40 Eslam M, George J. Genetic contibutions to NAFLD: leveraging shared genetics to uncover systems biology. Nat Rev Gastroenterol Hepatol. 2020; 17: 40-52.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/nrgastro.2013.182","article-title":"The genetics of NAFLD","volume":"10","author":"Anstee QM","year":"2013","unstructured":"41 Anstee QM, Day CP. The genetics of NAFLD. Nat Rev Gastroenterol Hepatol. 2013; 10: 645-655.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/ng.3714","article-title":"Integrative genomic analysis implicates limited peripheral adipose storage capacity in the pathogenesis of human insulin resistance","volume":"49","author":"42 Lotta","year":"2017","unstructured":"42 Lotta LA, Gulati P, Day FR, et al. Integrative genomic analysis implicates limited peripheral adipose storage capacity in the pathogenesis of human insulin resistance. Nat Genet. 2017; 49: 17-26.","journal-title":"Nat Genet"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"4369","DOI":"10.2337\/db14-0318","article-title":"Genetic evidence for a normal-weight \"metabolically obese\" phenotype linking insulin resistance, hypertension, coronary artery disease, and type 2 diabetes","volume":"63","author":"43 Yaghootkar","year":"2014","unstructured":"43 Yaghootkar H, Scott RA, White CC, et al. Genetic evidence for a normal-weight \"metabolically obese\" phenotype linking insulin resistance, hypertension, coronary artery disease, and type 2 diabetes. Diabetes 2014; 63: 4369-4377.","journal-title":"Diabetes"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"104","DOI":"10.3945\/ajcn.111.012369","article-title":"Genetic variation in PNPLA3 (adiponutrin) confers sensitivity to weight loss-induced decrease in liver fat in humans","volume":"94","author":"44 Sevastianova","year":"2011","unstructured":"44 Sevastianova K, Kotronen A, Gastaldelli A, et al. Genetic variation in PNPLA3 (adiponutrin) confers sensitivity to weight loss-induced decrease in liver fat in humans. Am J Clin Nutr. 2011; 94: 104-111.","journal-title":"Am J Clin Nutr"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1002\/hep.27490","article-title":"Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease","volume":"61","author":"45 Dongiovanni","year":"2015","unstructured":"45 Dongiovanni P, Petta S, Maglio C, et al. Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. Hepatology 2015; 61: 506-514.","journal-title":"Hepatology"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/ng.2901","article-title":"Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease","volume":"46","author":"46 Kozlitina","year":"2014","unstructured":"46 Kozlitina J, Smagris E, Stender S, et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2014; 46: 352-356.","journal-title":"Nat Genet"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"47 Mancina RM, Dongiovanni P, Petta S, et al. The MBOAT7-TMC4 variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of European Descent. Gastroenterology 2016; 150: 1219-1230.e6.","DOI":"10.1053\/j.gastro.2016.01.032"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"3935","DOI":"10.1007\/s11033-012-2470-6","article-title":"Association of glucokinase regulatory protein polymorphism with type 2 diabetes and fasting plasma glucose: a meta-analysis","volume":"40","author":"48 Li","year":"2013","unstructured":"48 Li H, Xu R, Peng X, et al. Association of glucokinase regulatory protein polymorphism with type 2 diabetes and fasting plasma glucose: a meta-analysis. Mol Biol Rep. 2013; 40: 3935-3942.","journal-title":"Mol Biol Rep"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1038\/ng.3977","article-title":"Exome-wide association study of plasma lipids in >300,000 individuals","volume":"49","author":"49 Liu","year":"2017","unstructured":"49 Liu DJ, Peloso GM, Yu H, et al. Exome-wide association study of plasma lipids in >300,000 individuals. Nat Genet. 2017; 49: 1758-1766.","journal-title":"Nat Genet"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1002\/hep.22659","article-title":"Transcription factor 7-like 2 polymorphism modulates glucose and lipid homeostasis, adipokine profile, and hepatocyte apoptosis in NASH","volume":"49","author":"50 Musso","year":"2009","unstructured":"50 Musso G, Gambino R, Pacini G, et al. Transcription factor 7-like 2 polymorphism modulates glucose and lipid homeostasis, adipokine profile, and hepatocyte apoptosis in NASH. Hepatology 2009; 49: 426-435.","journal-title":"Hepatology"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"51 Bj\u00f6rkstr\u00f6m K, St\u00e5l P, Hultcrantz R, et al Histologic scores for fat and fibrosis associate with development of type 2 diabetes in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2017; 15: 1461-1468.","DOI":"10.1016\/j.cgh.2017.04.040"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1111\/liv.14414","article-title":"The amount of liver fat predicts mortality and development of type 2 diabetes in non-alcoholic fatty liver disease","volume":"40","author":"52 Nasr","year":"2020","unstructured":"52 Nasr P, Fredrikson M, Ekstedt M, et al. The amount of liver fat predicts mortality and development of type 2 diabetes in non-alcoholic fatty liver disease. Liver Int. 2020; 40: 1069-1078.","journal-title":"Liver Int"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"717","DOI":"10.2337\/dc11-1853","article-title":"Combined influence of insulin resistance, overweight\/obesity, and fatty liver as risk factors for type 2 diabetes","volume":"35","author":"53 Sung","year":"2012","unstructured":"53 Sung KC, Jeong WS, Wild SH, et al. Combined influence of insulin resistance, overweight\/obesity, and fatty liver as risk factors for type 2 diabetes. Diabetes Care 2012; 35: 717-722.","journal-title":"Diabetes Care"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.jhep.2017.07.027","article-title":"Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD","volume":"67","author":"54 Hagstr\u00f6m","year":"2017","unstructured":"54 Hagstr\u00f6m H, Nasr P, Ekstedt M, et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J Hepatol. 2017; 67: 1265-1273.","journal-title":"J Hepatol"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"3637","DOI":"10.1210\/jc.2013-1519","article-title":"Resolution of fatty liver and risk of incident diabetes","volume":"98","author":"55 Sung","year":"2013","unstructured":"55 Sung KC, Wild SH, Byrne CD. Resolution of fatty liver and risk of incident diabetes. J Clin Endocrinol Metab. 2013; 98: 3637-3643.","journal-title":"J Clin Endocrinol Metab"},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"56 Musso G, Cassader M, Paschetta E, et al Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis. JAMA Intern Med. 2017; 177: 633-640.","DOI":"10.1001\/jamainternmed.2016.9607"},{"key":"ref56","doi-asserted-by":"publisher","unstructured":"57 American Diabetes Association. 4. Comprehensive medical evaluation and assessment of comorbidities: standards of medical care in diabetes - 2019. Diabetes Care 2019; 42(Suppl 1): S34-S45.","DOI":"10.2337\/dc19-S004"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"58 Chalasani","year":"2018","unstructured":"58 Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018; 67: 328-357.","journal-title":"Hepatology"},{"key":"ref58","doi-asserted-by":"publisher","unstructured":"59 European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016; 64: 1388-1402.","DOI":"10.1016\/j.jhep.2015.11.004"}],"container-title":["Orvosi Hetilap"],"original-title":[],"link":[{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/163\/21\/article-p815.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/650\/163\/21\/article-p815.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/650\/163\/21\/article-p815.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T11:48:48Z","timestamp":1698234528000},"score":1,"resource":{"primary":{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/163\/21\/article-p815.xml"}},"subtitle":["I. Patogenezis"],"short-title":[],"issued":{"date-parts":[[2022,5,22]]},"references-count":59,"journal-issue":{"issue":"21"},"URL":"https:\/\/doi.org\/10.1556\/650.2022.32479","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"value":"0030-6002","type":"print"},{"value":"1788-6120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,22]]}}}